Portola’s Bevyxxa Will Soon Secure a Critical Market Position in the VTE Space

21st December 2017 (Last Updated December 21st, 2017 13:52)

Portola Pharmaceuticals announced on December 19th that the FDA approved the company’s Prior Approval Supplement (PAS) for Bevyxxa (betrixaban) earlier than it was originally scheduled and therefore the commercial launch will initiate in early January.

Portola Pharmaceuticals announced on December 19th that the FDA approved the company’s Prior Approval Supplement (PAS) for Bevyxxa (betrixaban) earlier than it was originally scheduled and therefore the commercial launch will initiate in early January. This means that Bevyxxa will imminently bring relief to a patient population with an extremely high unmet need, as currently no anticoagulant therapy is approved for the prophylaxis of venous thromboembolism (VTE) for acute medically ill patients. It also means that Bevyxxa will secure a critical market position in this lucrative space, given the size of this population.

The acutely medically ill population includes patients with heart failure, stroke, infection, pulmonary disease, and overall any patients who are at risk for thromboembolic complications due to moderate or severe restricted mobility in either the hospital setting or post-discharge period. GlobalData epidemiologists estimate that the size of this population in seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) is over 23 million, which is a significantly high number of patients compared with the size of the patient pool requiring VTE treatment after the VTE event has already occurred.

The extended use of Bevyxxa in this large patient population will give Portola a great boost when entering into the novel oral anticoagulant (NOAC) space, where it will compete against established key players, J&J/Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa (dabigatran), BMS’ Eliquis (apixaban), and Daiichi Sankyo’s Savaysa (edoxaban). Although some of these therapies might be used off-label for VTE prophylaxis in acute medically ill patients, none have been granted approval for the treatment of this extended population yet.

In addition, the upcoming launch of Portola’s own Factor Xa reversal agent/antidote, andexanet alfa, which is currently in the pre-registration phase in the US and EU, will further boost Bevyxxa’s prospects. Since the approval of the first NOAC, Pradaxa, there has always been a level of hesitation among physicians and patients, mainly because of the lack of a reversal agent in the event of traumatic bleeding. Therefore, despite Portola being a relatively small company, with the approval of Bevyxxa in this large patient population with high unmet needs combined with the soon-to-come antidote that will offer an additional level of security to patients and physicians, the company is in a great position to conquer a large chunk of the lucrative VTE prophylaxis space.

 

 

Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions, and recommendations that GlobalData delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GlobalData can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect. This report is not a recommendation to purchase securities.